April 22nd, 22
Social Survey Research Information Co., Ltd.
Social Survey Research Information Co., Ltd.
NEWS
Launch of PatientsMap China 2022
AstraZeneca tops sales rep visit perception within many specialties in China
Japanese companies are also making their presence felt in their areas of strength
Social Survey Research Information Co., Ltd. and M3, Inc. launched PatientsMap 2022CN (China 2022 version) on March 31, 2022.
The data were obtained from a survey of member physicians on a portal site for medical professionals operated by Medlive.cn, an M3 Group company, with 11,000 physicians responding online.
In the survey, physicians were asked whether they had received sales rep visits from manufacturers.
The survey was conducted from the end of last year to the beginning of March of this year, and analysis was performed based on an understanding that the results were obtained during a near normal period of time, when the spread of COVID-19 was under control.
The results show that major Western companies ranked at the top in many specialties. (See Table 1)
AstraZeneca, in particular, had the highest rate of sales rep visit perception in many specialties. In oncology, three of the top five companies were local Chinese companies.
Japanese-affiliated companies also rank at the top in their respective areas of strength.
In gastroenterology, Takeda and Eisai were ranked 3rd and 5th, respectively. Sumitomo Pharma ranked 5th in psychiatry, Santen ranked 2nd in ophthalmology, and Astellas ranked 3rd in urology.
Other top-ranking companies were Otsuka, which ranked 9th in psychiatry, and Eisai, which ranked 6th in neurology.
The survey showed the degree to which Western companies are focusing on the Chinese market, as well as the fact that Japanese companies are also making their presence felt in their areas of strength.
(Table 1)
| Rank | Internal medicine n=1018 | Pulmonology n=534 | Cardiology n=1218 | Gastroenterology n=417 | Diabetology/ Endocrinology n=900 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AZ | 26.1 | AZ | 57.1 | AZ | 43.5 | AZ | 34.3 | Novo | 58.2 |
| 2 | Bayer | 21.6 | GSK | 38.2 | Novartis | 36.7 | CTTQ | 25.7 | AZ | 39.4 |
| 3 | Pfizer | 18.8 | CTTQ | 32.4 | Bayer | 36.5 | Takeda | 19.9 | Eli Lilly | 37.2 |
| 4 | Novo | 18.5 | Pfizer | 31.5 | Pfizer | 30.5 | Yangtze | 18.7 | Sanofi | 31.7 |
| 5 | MSD | 16.0 | Yangtze | 29.2 | Sanofi | 22.7 | Eisai | 16.5 | MSD | 26.9 |
| Rank | Psychiatry n=362 | Neurology n=1007 | Oncology n=561 | Ophthalmology n=191 | Urology n=294 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Jiangsu | 36.7 | Pfizer | 27.3 | AZ | 39.8 | Novartis | 49.2 | AZ | 49.3 |
| 2 | Janssen | 34.5 | Shijiazhuang | 26.7 | Jiangsu | 39.4 | Santen | 42.4 | Pfizer | 33.3 |
| 3 | Qilu | 34.0 | Bayer | 23.3 | CTTQ | 38.9 | Bayer | 25.7 | Astellas | 32.7 |
| 4 | Pfizer | 24.9 | AZ | 20.0 | Qilu | 37.6 | Qilu | 17.8 | Janssen | 31.6 |
| 5 | Sumitomo Pharma | 24.6 | Sanofi | 19.0 | Roche | 31.7 | J＆J | 15.7 | MSD | 30.3 |
Outline of PatientsMap 2022CN
Condition coverage: 402 conditions
Target respondents: Medlive.cn-registered physicians
Inclusion criteria: Physicians of all specialties at hospitals and clinics
Method: Online survey
Number of cooperating physicians: 11,106
Fieldwork period: December 27, 2021 to March 4, 2022
Survey topic: Conditions seen
Number of patients seen
Number of patients who were prescribed drugs
Conditions for which new drugs are desired
Sales rep visits
In Japan, this service will be jointly provided by Social Survey Research Information Co., Ltd. and M3, Inc.
■ Contact Information
Social Survey Research Information Co., Ltd.
E-mail: patientsmap@ssri.com
■ Social Survey Research Information Co., Ltd.
Established: April 1982
Capital: 27 million JPY
President & CEO: Takashi Makita
Number of employees: 137
Location: Head Office
NMF Shinjuku East Bldg. 2F, 3F
10-5 Tomihisacho, Shinjuku-ku, Tokyo 162-0067 JAPAN
Osaka office:
Daimei Bldg. 4F, 4-6-3 Hirano-cho, Chuo-ku, Osaka 541-0046
Affiliate companies: PD Research Co., Ltd.
MDB Co.
SSRI China Co., Ltd. (overseas subsidiary)
SSRI Asia Pacific Co., Ltd. (overseas subsidiary)
HIMA Research (overseas affiliate)
URL: http://www.ssri.com/
■ M3, Inc.
Established: September 2000
Capital: 29.036 billion JPY (as of March 31, 2021)
Representative Director: Itaru Tanimura
Number of employees, consolidated: 8,249 (as of March 31, 2021)
Location: Akasaka Intercity 10F 1-11-44 Akasaka, Minato-ku, Tokyo
URL: https://corporate.m3.com/